摘要:
Use of factor XIII for treating the symptoms of thrombocytopenia. A patient having thrombocytopenia, either chemically- or metabolically induced, is treated by administering factor XIII.
摘要:
Use of factor XIII for treating von Willebrand's disease. A patient having von Willebrand's disease is treated by administering factor XIII generally in conjunction with factor VIII concentrate, 1-desamino-8-D-arginine vasopressin (DDAVP) or desmopressin.
摘要:
The present invention provides two members of a new family of human proteins, designated as “Zven.” The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes.
摘要:
The present invention relates to polynucleotide and polypeptide molecules for zacrp3, a novel member of the family of proteins bearing a collage-like domain and a C1q domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zacrp3 polypeptides.
摘要:
The present invention provides two members of a new family of human proteins, designated as “Zven.” The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes.
摘要:
The present invention relates to polynucleotide and polypeptide molecules for use as inhibitors in hemostasis and immune function. Such inhibitors are members of the family of proteins bearing a collagen-like domain and a globular domain. The inhibitors are useful for promoting blood flow in the vasculature by reducing thrombogenic and complement activity. The inhibitors are also useful for pacifying collagenous surfaces and modulating wound healing.
摘要:
A method of modulating cytokine mediated hepatic injury by administering deltorphins to a mammal. Deltorphin I SEQ ID NO:1, deltorphin II SEQ ID NO:2 or combinations of deltorphins I SEQ ID NO:1 and II SEQ ID NO:2 may be administered. A deltorphin concentration in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade in a murine model of septic shock. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.
摘要翻译:通过向哺乳动物施用deltorphins来调节细胞因子介导的肝损伤的方法。 Deltorphin I SEQ ID NO:1,deltorphin II SEQ ID NO:2或deltorphins I SEQ ID NO:1和II SEQ ID NO:2的组合可以施用。 在生理上可接受的制剂中,约0.5mg / kg至约20mg / kg范围内的delphphin浓度阻断脓毒性休克鼠模型中的细胞因子级联。 因此公开了调节细胞因子介导的急性炎症,创伤诱导和毒素诱导的肝损伤的治疗方法,特别是通过肿瘤坏死因子调节。
摘要:
A method for treating ischemia by administering deltorphins to a mammal. Deltorphin I SEQ ID NO:1, delntorphin II SEQ ID NO:2 or combinations of deltorphins I SEQ ID NO:1 and II SEQ ID NO:2 may be administered. A deltorphin concentration of about 0.5-20 mg/kg body weight, or alternatively a lower concentration of about 1-1000 &mgr;g/kg body weight of the mammal in a physiologically acceptable formulation is administered up to four hours after an ischemic episode. Deltorphins may also be administered prior to or concurrently with onset of ischemia. Cerebral or spinal cord ischemia or ischemic heart disease may be treated using the method of the invention.
摘要翻译:一种通过向哺乳动物施用去铁蛋白来治疗缺血的方法。 可以给予Deltorphin I SEQ ID NO:1,delntorphin II SEQ ID NO:2或deltorphins I SEQ ID NO:1和II SEQ ID NO:2的组合。 在缺血发作后4小时内给药约0.5-20mg / kg体重的滴度,或者在生理上可接受的制剂中哺乳动物的约1-1000μg/ kg体重的较低浓度。 去头痛也可以在缺血发作之前或同时发生。 可以使用本发明的方法治疗脑或脊髓缺血或缺血性心脏病。
摘要:
The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
摘要:
Provided is a surgical applicator and applicator tip configured to attach in fluid communication, for the delivery of beneficial fluids. The applicator tip may also be configured to reversibly attach, in fluid communication, with a pledget. For example, the applicator tip may include male or female threads, and the pledget has threads that are complementary to the thread configuration of the tip. The applicator tip may further comprise at least one fluid transfer lumen for transfer of a fluid from the tip to the pledget. In one embodiment of the invention, the tip includes male threads and the pledget includes a pledget attachment portion. There are also provided methods for connecting the tip to the pledget. In one embodiment, a tip comprising male threads is attached to the pledget, comprising a pledget attachment portion, by tapping or pressing the tip into the pledget attachment portion. There are also provided methods of use for the attached tip and pledget, including debridement, tissue translocation, delivery of fluid substances, absorption of fluid substances and combinations thereof. In a particular embodiment, the applicator places a thrombin solution into the attached pledget for delivery of an active hemostatic agent to a tissue site.